ScripInsmed capitalized on the company’s better-than-expected Phase IIb clinical trial readout for treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH), which sent its s
ScripBiomedtracker’s latest report on biopharmaceutical company fundraising shows a 25.1% decline in year-over-year dollars raised, from $17.5bn in the fourth quarter of 2022 to $13.1bn in Q4 of 2023. Foll
ScripThe American Society of Clinical Oncology annual meeting often is followed by several follow-on public offerings (FOPOs) by small- to mid-sized public biotech companies reporting positive data at the
ScripBlueprint Medicines Corporation ’s presentation of full data from the Phase III PIONEER study of Ayvakit (avapritinib) in indolent systemic mastocytosis (ISM) bolsters the drug’s chances of winning ap